PARP inhibitors for the treatment of ovarian cancer

Expert: Ilaria Colombo, Oncology Institute of Southern Switzerland, Bellinzona, CH Questions: 1-Which is the mechanism of action of PARP inhibitors and why this is relevant in ovarian cancer? 2-How can we measure the homologous recombination deficiency? 3-Which is the current evidence for the use of maintenance PARP inhibitors in recurrent epithelial ovarian cancer? 4-Can you tell us which are the results of phase 3 trials that have investigated PARP inhibitors in front line treatment of epithelial ovarian cancer? 5-Which are the main toxicities of PARP inhibitors?